financetom
Business
financetom
/
Business
/
PRESS DIGEST-British Business - October 24
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PRESS DIGEST-British Business - October 24
Oct 23, 2025 9:47 PM

Oct 24 (Reuters) - The following are the top stories on

the business pages of British newspapers. Reuters has not

verified these stories and does not vouch for their accuracy.

The Times

- London-based Synthesia, which makes hyper-realistic AI

generated video, has rejected a $3 billion takeover proposal

from the U.S. tech company Adobe.

- The U.S. Food and Drug Administration has approved a

potential blockbuster blood cancer drug developed by GSK

, in a boost to the company's sales targets.

The Guardian

- Oil major TotalEnergies misled consumers in a

2021 ad campaign claiming it could become carbon neutral by

2050, a French civil court found on Thursday, in the first

decision applying France's greenwashing law to an energy

company.

- British finance minister Rachel Reeves is considering

raising income tax in next month's budget to help reduce a

multibillion-pound deficit.

The Telegraph

- Apple ( AAPL ) has lost a major class action lawsuit in

the UK paving the way for a possible 1.5 billion-pound ($2.01

billion) compensation payout to customers.

- U.S. President Donald Trump has pardoned the convicted

founder of cryptocurrency exchange Binance as the White House

unwinds a Biden-era crackdown on the digital assets industry.

Sky News

- Alphabet's Google has agreed to invest in an

instrument that could convert into an equity stake in THG

Ingenuity, the demerged arm of British e-commerce firm THG

, at a valuation of 750 million pounds.

($1 = 0.7451 pounds)

(Compiled by Bengaluru newsroom)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Nov 13, 2025
01:58 PM EST, 11/13/2025 (MT Newswires) -- Craig H Barratt, Director, on November 12, 2025, sold 750 shares in Intuitive Surgical ( ISRG ) for $435,000. Following the Form 4 filing with the SEC, Barratt has control over a total of 27,198 common shares of the company, with 27,198 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1035267/000127762025000008/xslF345X05/edgardoc.xml Price: 568.86, Change: -3.60, Percent Change:...
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Nov 13, 2025
IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cie, a venture studio, announced today that its portfolio company Nativo, a leading advertising technology provider, has entered into a definitive agreement to be acquired by Life360 ( LIF ) . The transaction, valued at approximately $120 million in cash and stock, marks another successful outcome of Cie’s venture studio model. Nativo joins...
Serve Robotics Shares Skid: What's Going On?
Serve Robotics Shares Skid: What's Going On?
Nov 13, 2025
Serve Robotics Inc ( SERV ) shares are trading lower on Thursday. The company disclosed its financial results for the third quarter. SERV is underperforming relative to peers. Get the market research here. What To Know: Serve Robotics ( SERV ) reported quarterly losses of 40 cents per share, versus the analyst consensus estimate for losses of 33 cents per share....
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Nov 13, 2025
Gilead Sciences Inc ( GILD ). on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). • GILD shares are testing new highs. Check the market position here....
Copyright 2023-2026 - www.financetom.com All Rights Reserved